Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chinyu Su

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Rheumatology and Therapy|December 16, 2022
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development ProgramsKevin L Winthrop, Arne Yndestad, Dan Henrohn, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2020
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' replyBruce E Sands, Alessandro Armuzzi, John K Marshall, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2019
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE OpenBruce E Sands, Alessandro Armuzzi, John K Marshall, et al.
The New England Journal of Medicine|May 4, 2017
Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Chinyu Su, Bruce E Sands, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Rheumatology and Therapy|December 16, 2022
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development ProgramsKevin L Winthrop, Arne Yndestad, Dan Henrohn, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2025
Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a double-blind, placebo-controlled, randomised, phase 2 trialEvan S Dellon, Margaret H Collins, Albert J Bredenoord, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2020
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' replyBruce E Sands, Alessandro Armuzzi, John K Marshall, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2019
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE OpenBruce E Sands, Alessandro Armuzzi, John K Marshall, et al.
The New England Journal of Medicine|May 4, 2017
Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Chinyu Su, Bruce E Sands, et al.
Pageof 7